Conflicting cerebrospinal fluid biomarkers and progression to dementia due to Alzheimer's disease
File(s)
Published version
Author(s)
Type
Journal Article
Abstract
Background:
According to new diagnostic guidelines for Alzheimer’s disease (AD), biomarkers enable estimation of
the individual likelihood of underlying AD pathophysiology and the associated risk of progression to AD dementia
for patients with mild cognitive impairment (MCI). Nonetheless, how conflicting biomarker constellations affect
the progression risk is still elusive. The present study explored the impact of different cerebrospinal fluid (CSF)
biomarker constellations on the progression risk of MCI patients.
Methods:
A multicentre cohort of 469 patients with MCI and available CSF biomarker results and clinical follow-up
data was considered. Biomarker values were categorized as positive for AD, negative or borderline. Progression risk
differences between patients with different constellations of total Tau (t-Tau), phosphorylated Tau at threonine 181
(p-Tau) and amyloid-beta 1
–
42 (A
β
42
) were studied. Group comparison analyses and Cox regression models
were employed.
Results:
Patients with all biomarkers positive for AD (
N
= 145) had the highest hazard for progression to dementia
due to AD, whilst patients with no positive biomarkers (
N
= 111) had the lowest. The risk of patients with only
abnormal p-Tau and/or t-Tau (
N
= 49) or with positive A
β
42
in combination with positive t-Tau or p-Tau (
N
= 119) is
significantly lower than that of patients with all biomarkers positive.
Conclusions:
The risk of progression to dementia due to AD differs between patients with different CSF biomarker
constellations.
According to new diagnostic guidelines for Alzheimer’s disease (AD), biomarkers enable estimation of
the individual likelihood of underlying AD pathophysiology and the associated risk of progression to AD dementia
for patients with mild cognitive impairment (MCI). Nonetheless, how conflicting biomarker constellations affect
the progression risk is still elusive. The present study explored the impact of different cerebrospinal fluid (CSF)
biomarker constellations on the progression risk of MCI patients.
Methods:
A multicentre cohort of 469 patients with MCI and available CSF biomarker results and clinical follow-up
data was considered. Biomarker values were categorized as positive for AD, negative or borderline. Progression risk
differences between patients with different constellations of total Tau (t-Tau), phosphorylated Tau at threonine 181
(p-Tau) and amyloid-beta 1
–
42 (A
β
42
) were studied. Group comparison analyses and Cox regression models
were employed.
Results:
Patients with all biomarkers positive for AD (
N
= 145) had the highest hazard for progression to dementia
due to AD, whilst patients with no positive biomarkers (
N
= 111) had the lowest. The risk of patients with only
abnormal p-Tau and/or t-Tau (
N
= 49) or with positive A
β
42
in combination with positive t-Tau or p-Tau (
N
= 119) is
significantly lower than that of patients with all biomarkers positive.
Conclusions:
The risk of progression to dementia due to AD differs between patients with different CSF biomarker
constellations.
Date Issued
2016-12-09
Date Acceptance
2016-10-28
Citation
Alzheimer's Research & Therapy, 2016, 8 (1)
ISSN
1758-9193
Publisher
BioMed Central
Journal / Book Title
Alzheimer's Research & Therapy
Volume
8
Issue
1
Copyright Statement
© The Author(s). 2016. Open Access. This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Identifier
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000391149000001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
Subjects
Science & Technology
Life Sciences & Biomedicine
Clinical Neurology
Neurosciences
Neurosciences & Neurology
Prognosis
Alzheimer's disease
Mild cognitive impairment
Cerebrospinal fluid
MILD COGNITIVE IMPAIRMENT
NEUROIMAGING INITIATIVE SUBJECTS
CSF BIOMARKERS
NATIONAL INSTITUTE
ASSOCIATION WORKGROUPS
DIAGNOSTIC GUIDELINES
CLINICAL-PRACTICE
MEMORY CLINICS
MCI PATIENTS
TAU LEVELS
Alzheimer’s disease
11 Medical And Health Sciences
Publication Status
Published
Article Number
ARTN 51